English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia, which confers a risk of stroke and thrombo-embolism,1 and thromboprophylaxis is recommended with oral anticoagulation for those at moderate-to-high risk of stroke.2 Antiplatelet therapy is clearly less effective for stroke prevention than vitamin K antagonists (VKAs).Dual antiplatelet therapy, in contrast, is recommended after coronary artery stenting to reduce the increased risk of stent thrombosis.3 Oral anticoagulant therapy is less effective after stenting,4 reflecting the pathophysiology of platelet-rich thrombus in stents, and so the need to inhibit platelet aggregation to prevent stent thrombosis.Given that AF commonly co-exists with vascular disease, increasing numbers of AF patients undergo percutaneous coronary artery interventions (PCI). However, there are limited data … *Corresponding author. Tel: +34 968369445, Fax: +34 968369662, Email: fcomarino{at}hotmail.com

europace

Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence